Why the study?
Despite immediate reperfusion after acute myocardial infarction improving outcomes, patients remain at high risk for mortality and morbidity, with ischemia-reperfusion injury playing a major role.
Does targeted pharmacotherapy reduce ischemia-reperfusion injury in patients with acute myocardial infarction?
Does targeted pharmacotherapy reduce ischemia-reperfusion injury in patients with acute myocardial infarction?
Despite promising preclinical data, targeted pharmacotherapies for ischemia-reperfusion injury in acute myocardial infarction have not yet shown consistent success in large clinical trials, highlighting the need for individualized approaches.
Answers are grounded in this paper and cite their sources.
No IRI pharmacotherapy warrants routine post-AMI use; leaves open need for refined targets and trial designs.
INTRODUCTION: Achieving reperfusion immediately after acute myocardial infarction improves outcomes; despite this, patients remain at a high risk for mortality and morbidity at least for the first year after the event. Ischemia-reperfusion injury (IRI) has a complex pathophysiology and plays an important role in myocardial tissue injury, repair, and remodeling. AREAS COVERED: In this review, the authors discuss the various mechanisms and their pharmacological agents currently available for reducing myocardial ischemia-reperfusion injury (IRI). They review important original investigations and trials in various clinical databases for treatments targeting IRI. EXPERT OPINION: Encouraging results observed in many preclinical studies failed to show similar success in attenuating myocardial IRI in large-scale clinical trials. Identification of critical risk factors for IRI and targeting them individually rather than one size fits all approach should be the major focus of future research. Various newer therapies like tocilizumab, anakinra, colchicine, revacept, and therapies targeting the reperfusion injury salvage kinase pathway, survivor activating factor enhancement, mitochondrial pathways, and angiopoietin-like peptide 4 hold promise for the future.
No takes yet. Share an insight, caveat, or question.
Rout et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: